tucatinib

EGFR-sparing HER2 kinase inhibitor

approved in met. HER2+ BC incl. w/ brain met.

from optimization of known TKIs

Mol. Cancer Ther., Apr. 1, 2020

Array / Cascadian Tx / Seattle Genetics

Tucatinib is the third approved HER2 kinase inhibitor (after lapatinib and neratinib), but differentiates itself due to its selectivity against the closely related EGFR, which is hypothesized to be a…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.